Gastroentérologie et hépatologie : ce qui a changé en 2025

The year 2025 saw major advances in gastroenterology and hepatology. Having long been overshadowed by other chronic viral hepatitis, Hepatitis D now benefits from new therapeutic options, including bulevirtide, offering markedly improved clinical prospects. In metabolic dysfunction-associated steatotic liver disease, semaglutide has generated strong interest, with promising outcomes in fibrotic steatohepatitis, underscoring the close link between metabolism and liver health. Finally, endo-hepatology is emerging as an innovative tool for both the evaluation and targeted management of portal hypertension, while metabolic endoscopic techniques are paving the way for promising minimally invasive alternatives. This article aims to provide an in-depth overview of these recent developments and to discuss their implications for everyday clinical practice.